ERLOTINIB HYDROCHLORIDE Drug Patent Profile

When do Erlotinib Hydrochloride patents expire, and what generic alternatives are available?

Erlotinib Hydrochloride is a drug marketed by Accord Hlthcare, Alembic, Apotex, Chartwell Rx, Eugia Pharma, Hetero Labs Ltd V, MSN, Natco Pharma Ltd, Rising, Shilpa, Sun Pharm, Teva Pharms Usa Inc, and Zydus Pharms. and is included in thirteen NDAs.

The generic ingredient in ERLOTINIB HYDROCHLORIDE is erlotinib hydrochloride. There are twenty-five drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the erlotinib hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Erlotinib Hydrochloride

A generic version of ERLOTINIB HYDROCHLORIDE was approved as erlotinib hydrochloride by RISING on June 11^th, 2014.

Summary for ERLOTINIB HYDROCHLORIDE

US Patents:	0
Applicants:	13
NDAs:	13
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	838
Patent Applications:	1,830
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ERLOTINIB HYDROCHLORIDE
DailyMed Link:	ERLOTINIB HYDROCHLORIDE at DailyMed

Recent Clinical Trials for ERLOTINIB HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	PHASE1
Northwestern University	PHASE1
Mayo Clinic	PHASE2

See all ERLOTINIB HYDROCHLORIDE clinical trials

Pharmacology for ERLOTINIB HYDROCHLORIDE

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Medical Subject Heading (MeSH) Categories for ERLOTINIB HYDROCHLORIDE

Antineoplastic Agents

Protein Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ERLOTINIB HYDROCHLORIDE

L01EB	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for ERLOTINIB HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TARCEVA	Tablets	erlotinib hydrochloride	25 mg	021743	1	2008-11-18

US Patents and Regulatory Information for ERLOTINIB HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	ERLOTINIB HYDROCHLORIDE	erlotinib hydrochloride	TABLET;ORAL	210300-003	Nov 5, 2019		DISCN	No	No
Shilpa	ERLOTINIB HYDROCHLORIDE	erlotinib hydrochloride	TABLET;ORAL	211960-002	Nov 5, 2019	AB	RX	No	No
Teva Pharms Usa Inc	ERLOTINIB HYDROCHLORIDE	erlotinib hydrochloride	TABLET;ORAL	091059-001	Nov 9, 2020	AB	RX	No	No

Market Dynamics and Financial Trajectory for Erlotinib Hydrochloride

Last updated: February 19, 2026

Erlotinib hydrochloride, marketed primarily as Tarceva, is an epidermal growth factor receptor (EGFR) inhibitor approved for non-small cell lung cancer (NSCLC) and pancreatic cancer. Its market trajectory depends on clinical efficacy, competitive landscape, regulatory factors, and pricing strategies.

Market Overview

Erlotinib hydrochloride addresses a multi-billion dollar segment comprising targeted cancer therapies. The global oncology drug market was valued at approximately USD 147 billion in 2022 and expected to grow at a compound annual growth rate (CAGR) of 7.3% through 2030 [1].

In 2022, the lung cancer segment represented over USD 20 billion worldwide, with targeted therapies like Erlotinib capturing significant shares. The pancreatic cancer segment also contributes, although it remains comparatively smaller.

Key Market Drivers

• Regulatory approvals: Erlotinib gained FDA approval in 2004 for NSCLC and expanded approvals into other indications. Regulatory decisions affect market access and sales potential.

• Combination therapies: Research integrating Erlotinib into combination regimens enhances its therapeutic scope and market penetration.

• Biomarker testing: EGFR mutation testing increases patient selection accuracy, improving outcomes and sales.

Market Challenges

• Competition: First-generation EGFR inhibitors like Gefitinib and newer agents such as Osimertinib (AstraZeneca) threaten market share.

• Resistance development: Acquired resistance limits long-term efficacy; secondary mutations like T790M reduce drug effectiveness.

• Pricing pressures: Cost containment efforts and biosimilar entries in future years will exert downward pressure on pricing.

Regulatory and Patent Landscape

• Patent expiry: The original patent expired in the EU in 2015 and in the US in 2019. Generic versions are now available, reducing revenue potential for branded versions.

• Regulatory designations: Orphan drug status and accelerated approvals in certain jurisdictions can influence market dynamics.

Revenue Forecasts

Estimates vary, but projected sales of Erlotinib are expected to decline gradually over the next five years due to patent expiries and competition, unless new indications or formulations emerge.

Year	Estimated Global Revenue	Notes
2022	USD 2.2 billion	Peak sales driven by lung and pancreatic indications
2023	USD 1.8 billion	Post-patent expiry effects begin to show
2025	USD 1.2 billion	Competitive pressures intensify; generic uptake increases
2030	USD 700 million	Market penetration of generics and biosimilars reduce revenue

Strategic Considerations

• Patent extensions: No current patents extend beyond 2024; companies explore new drug combinations or formulations to extend product lifecycle.

• Orphan drug status: Expanding indications into orphan cancer subtypes may slow revenue decline.

• Market segmentation: Targeting emerging markets with lower prices; investing in companion diagnostics to improve patient selection.

Conclusion

Erlotinib hydrochloride has experienced robust initial sales with a peak around 2022, followed by decline due to patent expiries and increased competition. Future growth hinges on new indications, combination therapies, and regulatory incentives.

Key Takeaways

• The global oncology market remains ripe but competitive, with targeted treatments like Erlotinib facing patent expiration-driven erosion.
• Patent expiries in 2019 and upcoming expiration opportunities limit revenue potential unless novel uses or formulations are developed.
• Competition from third-generation EGFR inhibitors has impacted market share, with osimertinib gaining prominence.
• Market growth depends on expansion into emerging markets, biomarker-driven strategies, and potential label expansions.
• Revenue projections over the next five years suggest a declining trend, from USD 1.8 billion in 2023 to approximately USD 700 million in 2030.

FAQs

Q1: How has patent expiry affected Erlotinib's market?
Patent expiry in 2019 opened the market to generic competitors, sharply reducing prices and sales volume for the branded drug.

Q2: What are the main competitors to Erlotinib?
Osimertinib (AstraZeneca), Gefitinib (Astellas), and other third-generation EGFR inhibitors are primary competitors, especially in resistant NSCLC cases.

Q3: Can Erlotinib regain market share?
Potentially, through new indications, combination therapies, or improved diagnostic tools; however, generic competition constrains recovery.

Q4: What is the outlook for Erlotinib in emerging markets?
Price-sensitive markets may see ongoing demand, especially with local manufacturing and lower-cost generics; growth is limited compared to developed markets.

Q5: Will biosimilars impact Erlotinib’s future sales?
Biosimilars are unlikely; Erlotinib is a small-molecule drug, for which generics mainly affect pricing and volume rather than biosimilar competition.

---

References

[1] Grand View Research. (2022). Oncology Drugs Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/oncology-drugs-market